MedWatch

Nordea: Another Amylin-owner would have been stronger

Bristol-Myers Squibb’s acquisition of Amylin Pharmaceuticals will, according to Nordea, lead to a better marketing-machine, but the bank would have seen another international actor as a stronger owner.

Foto: bristol meyer squibb/ PR

Bristol-Myers Squibb has spent DKK 40 billion on Amylin, but the pharmaceutical group is not the strongest partner for the diabetes drug company. Sanofi would have been a better option.

That’s the unmistakable point of view expressed in a report from Nordea yesterday.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier